Polycythemia historical perspective: Difference between revisions
| Line 10: | Line 10: | ||
Polycythemia vera was first mentioned in 1892 in the medical literature by a French physician Louis Henri Vaquez. | Polycythemia vera was first mentioned in 1892 in the medical literature by a French physician Louis Henri Vaquez. | ||
In 1899 and 1900 two additional cases of polycythemia vera were described by Richard Clark Cabot both with increased erythrocytes and leukocytes and one with marked splenomegaly. | |||
In 1951, William Dameshek grouped together chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, primary myelofibrosis, and erythroleukemia and coined the term "myeloproliferative disorders". | |||
In 2005, a gain of function mutation in JAK2 (JAK2V617F) was first implicated in the pathogenesis of BCR-ABL negative myeloproliferative disorders. | |||
===Landmark Events in the Development of Treatment Strategies=== | ===Landmark Events in the Development of Treatment Strategies=== | ||
Revision as of 03:26, 3 December 2020
|
Polycythemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Polycythemia historical perspective On the Web |
|
American Roentgen Ray Society Images of Polycythemia historical perspective |
|
Risk calculators and risk factors for Polycythemia historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Debduti Mukhopadhyay, M.B.B.S[2]
Overview
Historical Perspective
Discovery
Polycythemia vera was first mentioned in 1892 in the medical literature by a French physician Louis Henri Vaquez.
In 1899 and 1900 two additional cases of polycythemia vera were described by Richard Clark Cabot both with increased erythrocytes and leukocytes and one with marked splenomegaly. In 1951, William Dameshek grouped together chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, primary myelofibrosis, and erythroleukemia and coined the term "myeloproliferative disorders". In 2005, a gain of function mutation in JAK2 (JAK2V617F) was first implicated in the pathogenesis of BCR-ABL negative myeloproliferative disorders.
Landmark Events in the Development of Treatment Strategies
Impact on Cultural History
Famous Cases
The following are a few famous cases of [disease name]: